Financials data is unavailable for this security.
View more
Year on year Cidara Therapeutics Inc had relatively flat revenues (64.45m to 63.91m), though the company grew net income from a loss of 33.58m to a smaller loss of 22.93m. A reduction in the selling, general and administrative costs as a percentage of sales from 31.88% to 28.69% was a component in the net income growth despite flat revenues.
Gross margin | 91.14% |
---|---|
Net profit margin | -367.91% |
Operating margin | -377.36% |
Return on assets | -96.27% |
---|---|
Return on equity | -158.76% |
Return on investment | -136.45% |
More ▼
Cash flow in USDView more
In 2023, Cidara Therapeutics Inc increased its cash reserves by 9.31%, or 3.05m. Cash Flow from Financing totalled 25.98m or 40.66% of revenues. In addition the company used 22.43m for operations while cash used for investing totalled 505.00k.
Cash flow per share | -25.55 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 28.66 |
---|---|
Tangible book value per share | 28.66 |
More ▼
Balance sheet in USDView more
Current ratio | 4.25 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.0053 |
---|---|
Total debt/total capital | 0.0053 |
More ▼